手性药物在诊断学中的应用潜力
Application Potential of Chiral Drugs in Diagnostics
DOI: 10.12677/MD.2019.91006, PDF,   
作者: 韩建冬, 王美玲, 格根塔娜, 杜艳青, 梁凤英, 额尔敦*：内蒙古医科大学，内蒙古 呼和浩特
关键词: 手性；手性药物；诊断学；Chirality； Chiral Drugs； Diagnostics
摘要: 近年来，手性药物在临床诊断学上引起人们的广泛关注，手性药物的开发已成为国际研究的热点。本文对手性和手性药物的概念、研究的实际意义以及手性药物在诊断学中的应用研究现状进行阐述，说明手性药物具有广阔的市场前景。综述了目前实验室和工业生产领域手性药物的拆分方法，包括：结晶拆分法，化学拆分法，动力学拆分法，生物拆分法，色谱拆分法，手性萃取拆分法和膜拆分法等，并简要介绍了每种方法的情况及优缺点。手性药物的研究与开发，已经成为当今世界新药发展的重要方向和热点领域。正在开发中的手性药物有三分之二是手性的。据专家预测，到2025年，全球上市的化学合成新药中约有80%的为单一对映体手性药物。这些数字充分体现了手性药物手性化的浪潮，手性药物的不断增加改变着化学手性药物的构成，成为制药工业的新宠儿，在诊断学中发挥更大的应用。
Abstract: In recent years, chiral drugs have attracted widespread attention in clinical diagnostics. The de-velopment of chiral drugs has become a hot spot in international research. This article describes the concept of chirality and chiral drugs, the practical significance of the research, and the current research status of chiral drugs in diagnostics, indicating that chiral drugs have broad market pro-spects. The current methods for the separation of chiral drugs in laboratory and industrial pro-duction are reviewed, including: crystallographic resolution, chemical resolution, kinetic resolution, biological resolution, chromatographic resolution, chiral extraction method and membrane splitting method, etc., and it briefly introduces the situation, advantages and disadvantages of each method. The research and development of chiral drugs have become an important direction and hotspot of new drug development in the world today. Two-thirds of chiral drugs under development are chiral. According to experts’ prediction, by 2025, about 80% of the new chemical synthetic drugs listed globally are single enantiomer chiral drugs. These figures fully reflect the wave of chiralization of chiral drugs. The increasing number of chiral drugs has changed the composition of chemical chiral drugs, becoming the new darling of the pharmaceutical industry, making it a greater application in diagnostics.
文章引用：韩建冬, 王美玲, 格根塔娜, 杜艳青, 梁凤英, 额尔敦. 手性药物在诊断学中的应用潜力[J]. 医学诊断, 2019, 9(1): 29-33. https://doi.org/10.12677/MD.2019.91006

参考文献

[1] 官家乐, 高原, 高鸿慈. 手性药物[J]. 中国医院医学杂志, 2001, 21(7): 443-445.
[2] 马纪伟, 闰东良. 手性和手性药物[J]. 井冈山医专学报, 2005, 12(3): 24-26.
[3] 顿彬, 刘会臣. 手性药物对映体在药效学与药代动力学的相互作用[J]. 中国临床药理学杂志, 2005, 22(1): 66-69.
[4] 杜建红, 夏叔泉. 手性药物发展中的外消旋体和对映体[J]. 国外医药-合成药、生化药、制剂分册(world pharmacy), 1994, 15(4): 206-208.
[5] Turk, E., Zabel, B., Mundlos, S., et al. (1991) Glucose/Galactose Malabsorption Caused by a Defect in the Na+/Glucose Cotransporter. Nature, 350, 354-356. [Google Scholar] [CrossRef] [PubMed]
[6] 孟飞. 手性药物开发战略及研究进展[J]. 医药化工, 2004(8): 12-18.
[7] 王艳波, 张瑛, 聂文辉. 开发生产手性药物的重要意义[J]. 首都医药, 2005, 12(22): 25.
[8] 华维一, 许国友. 手性药物手性、药理作用与新药开发[J]. 现代应用医学, 1993, 10(3): 4-7.
[9] Yamate, J., Sato, K., Ide, M., et al. (2002) Participation of Different Macrophage Populations and Myofibroblastic Cells in Chronically Developed Renal Interstitial Fibrosis after Cisplatin-Induced Renal Injury in Rats. Veterinary Pathology, 39, 322-333. [Google Scholar] [CrossRef] [PubMed]
[10] 白蕾, 霍淑慧, 陈晶. 用于手性识别α-氨基酸的方酰胺荧光探针分子[J]. 分析化学, 2019, 40(1): 41-46.
[11] 朱宇萍, 倪萍. 还原氧化石墨烯/硫堇复合物修饰的手性表面对色氨酸的选择性识别[J]. 吉林大学学报（理学版）, 2018, 56(5): 1278-1284.
[12] 吴超飞. 手性溶剂化法识别的研究进展[J]. 开发与应用, 2018, 47(6): 546-548.
[13] Kawano, S., Horikawa, M., Yasohara, Y., et al. (2003) Microbial Enztioselective Reduction of Acetylpyridine Derivatives. Bioscience, Biotechnology, and Biochemistry, 67, 809-815. [Google Scholar] [CrossRef] [PubMed]
[14] 郭莉娜, 陈灿, 黄明智, 等. 不对称催化反应合成手性药物的研究进展[J]. 精细化工中间体, 2006, 36(2): 1-5.
[15] 丁慈. 手性药物的开发与前景[J]. 中国医药情报, 1998(4): 83-85.
[16] 王普善, 王宇梅. 手性药物开发战略的再认识[J]. 精细与专用化学品, 2004, 12(10): 4-7.
[17] Kanai, Y., Lee, W.S., You, G., et al. (1994) The Human Kidney Low Affinity Na+/Glucose Cotransporter SGLT2. Delineation of the Major Renal Reabsorptive Mechanism for D-Glucose. Journal of Clinical Investigation, 93, 397-404. [Google Scholar] [CrossRef] 
[18] 张宇. 手性药物研究取得重要进展[J]. 中国医药技术与市场, 2005, 5(4): 37.
[19] 丁慈. 手性药物研究进展和国内市场[J]. 制药原料及中间体信息, 2005(12): 27-28.
[20] 钱鸣蓉, 陈亚坤, 曾苏. 手性药物的研究策略[J]. 中国现代应用医学, 2004, 21(6): 461-464.
[21] Jin, D.Q., Yin, S.N. and Mu, Y.M. (2007) Advance in Research of PPAR. Chinese Journal of Drug Application and Monitoring, 4, 46-49.
[22] Cai, L. and Liu, P. (2010) Dipeptidyl Peptidase IV Inhibitors: A New Class of Oral Agents for Treatment of Type 2 Diabetes Mellitus. Journal of International Pharmaceutical Research, 37, 361-365.
[23] Tong, S.Q., Guan, Y.X., Yan, J.Z., et al. (2011) Enantiomeric Separation of (R,S)-Naproxen by Recycling High Speed Counter-Current Chromatography with Hydroxypropyl-β-cyclodextrin as Chiral Selector. Journal of Chromatography A, 1218, 5434-5440. [Google Scholar] [CrossRef] [PubMed]
[24] 谢娜. 高速逆流色谱拆分酮康唑等三种手性药物的研究[D]: [硕士学位论文]. 湘潭: 湘潭大学, 2016.
[25] Ennarz, W.J. (2006) Encyclopedia of Biological Chem-istry. Science Press, 208-212.
[26] Hediger, M.A. and Rhoads, D.B. (1994) Molecular Physiology of Sodium-Glucose Cotransporters. Physiological Reviews, 74, 993-1026. [Google Scholar] [CrossRef] [PubMed]
[27] 成化. “手性药物国家工程研究中心”项目通过评估[J]. 中国西部科技, 2005(11): 15.
[28] List, J.F., Woo, V., Morales, E., et al. (2009) Sodium-Glucose Cotransport Inhibition with Dapagliflozin in Type 2 Diabetes. Diabetes Care, 32, 650-657. [Google Scholar] [CrossRef] [PubMed]
[29] Ehrenkranz, J.R.L., Lewis, N.G., Kahn, C.R., et al. (2005) Phlorizin: A Review. Diabetes/Metabolism Research and Reviews, 21, 31-38. [Google Scholar] [CrossRef] [PubMed]
[30] 李全, 谢毓云. 手性药物的光学异构体与药效[J]. 中国手性药物化学杂志, 1996, 6(2): 151-154.
[31] 于平, 岑沛霖, 励建荣. 手性化合物制备的方法[J]. 生物工程进展, 2001, 21(6): 89-92.
[32] Imamura, M., Murakami, T., Shiraki, R., et al. (2004) C-Glycoside Derivatives and Salts There of. PCT/JP2004/0033324. 2004-12-03.
[33] Mascitti, V. and Ville, C.P. (2010) Stereoselective Synthesis of a Dioxa-Bicyclo[3.2.1]octane SGLT2 Inhibitor. Organic Letters, 12, 2940-2943. [Google Scholar] [CrossRef] [PubMed]